NRIX
Nurix Therapeutics, Inc.
Price Chart
Latest Quote
$18.65
+1.10 (+6.27%)
Current Price
| Previous Close | $17.55 |
| Open | $17.83 |
| Day High | $18.85 |
| Day Low | $17.83 |
| Volume | 1,256,114 |
Stock Information
| Shares Outstanding | 103.41M |
| Total Debt | $58.66M |
| Cash Equivalents | $540.73M |
| Revenue | $71.78M |
| Net Income | $-295.28M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.95B |
| EPS (TTM) | $-3.17 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.45B |
| Sales | $71.78M |
| Income | $-295.28M |
| Book/sh | $4.65 |
| Cash/sh | $5.23 |
| Employees | 317 |
Financial Ratios
| Quick Ratio | 5.89 |
| Current Ratio | 6.01 |
| Debt/Eq | 12.20 |
Returns & Margins
| ROA | -31.50% |
| ROE | -61.40% |
| Operating Margin | -1479.45% |
Ownership
| Insider Ownership | 1.09% |
| Institutional Ownership | 114.96% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.06 |
| P/S | 27.17 |
| P/B | 4.06 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $31.44 |
Technical Indicators
| SMA20 | $16.81 |
| SMA50 | $16.65 |
| SMA200 | $15.17 |
| RSI | 68.61 |
| ATR | 1.4096 |
| Shares Float | 82.41M |
| Short Float | 18.90% |
| Short Ratio | 18.61 |
| Volatility | 1.87 |
| Rel Volume | 0.50 |
Performance History
| Week | +10.68% |
| Month | +7.59% |
| Quarter | +28.39% |
| 6 Months | +4.72% |
| YTD | +4.43% |
| Year | +64.14% |
| 3 Years | +69.76% |
| 5 Years | -37.76% |
| 10 Years | -0.79% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $18.86 | 1,572,662 |
| 2026-06-22 | $18.65 | 2,214,300 |
| 2026-06-18 | $17.55 | 4,250,800 |
| 2026-06-17 | $17.12 | 2,513,900 |
| 2026-06-16 | $17.07 | 2,675,700 |
| 2026-06-15 | $17.04 | 2,684,000 |
| 2026-06-12 | $16.95 | 2,561,600 |
| 2026-06-11 | $16.98 | 4,030,400 |
| 2026-06-10 | $15.30 | 2,539,700 |
| 2026-06-09 | $15.64 | 6,665,200 |
| 2026-06-08 | $15.64 | 21,065,100 |
| 2026-06-05 | $14.64 | 1,633,000 |
| 2026-06-04 | $15.28 | 1,578,300 |
| 2026-06-03 | $15.48 | 1,326,100 |
| 2026-06-02 | $16.37 | 1,050,500 |
| 2026-06-01 | $17.39 | 851,600 |
| 2026-05-29 | $17.76 | 1,157,200 |
| 2026-05-28 | $17.67 | 866,500 |
| 2026-05-27 | $17.47 | 831,200 |
| 2026-05-26 | $17.38 | 1,029,400 |
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
đ° Latest News
Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst Target
Simply Wall St. âĸ 2026-06-16T15:08:38Z
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)
Insider Monkey âĸ 2026-06-16T12:54:07Z
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-06-15T12:20:02Z
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-11T09:12:00Z
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
Zacks âĸ 2026-06-09T10:21:00Z
Company News for Jun 9, 2026
Zacks âĸ 2026-06-09T08:27:00Z
Broader Market Settles Higher as Chipmakers Rally
Barchart âĸ 2026-06-08T20:33:03Z
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
Investor's Business Daily âĸ 2026-06-08T20:03:44Z
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
GuruFocus.com âĸ 2026-06-08T19:35:48ZRoche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion
The Wall Street Journal âĸ 2026-06-08T15:44:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $83,980,000 | $54,549,000 | $76,987,000 | $38,627,000 |
| Operating Revenue | $83,980,000 | $54,549,000 | $76,987,000 | $38,627,000 |
| Expenses | ||||
| Total Expenses | $369,646,000 | $267,576,000 | $232,050,000 | $222,494,000 |
| Net Non Operating Interest Income Expense | $21,969,000 | $19,728,000 | $11,115,000 | $3,507,000 |
| Operating Expense | $369,646,000 | $267,576,000 | $232,050,000 | $222,494,000 |
| General And Administrative Expense | $52,743,000 | $45,944,000 | $42,902,000 | $37,997,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-264,457,000 | $-193,569,000 | $-143,948,000 | $-180,360,000 |
| Net Interest Income | $21,969,000 | $19,728,000 | $11,115,000 | $3,507,000 |
| Interest Income | $21,969,000 | $19,728,000 | $11,115,000 | $3,507,000 |
| Normalized Income | $-264,457,000 | $-193,569,000 | $-143,948,000 | $-180,360,000 |
| Net Income From Continuing And Discontinued Operation | $-264,457,000 | $-193,569,000 | $-143,948,000 | $-180,360,000 |
| Total Operating Income As Reported | $-285,666,000 | $-213,027,000 | $-155,063,000 | $-183,867,000 |
| Net Income Common Stockholders | $-264,457,000 | $-193,569,000 | $-143,948,000 | $-180,360,000 |
| Net Income | $-264,457,000 | $-193,569,000 | $-143,948,000 | $-180,360,000 |
| Net Income Including Noncontrolling Interests | $-264,457,000 | $-193,569,000 | $-143,948,000 | $-180,360,000 |
| Net Income Continuous Operations | $-264,457,000 | $-193,569,000 | $-143,948,000 | $-180,360,000 |
| Pretax Income | $-263,697,000 | $-193,299,000 | $-143,948,000 | $-180,360,000 |
| Interest Income Non Operating | $21,969,000 | $19,728,000 | $11,115,000 | $3,507,000 |
| Operating Income | $-285,666,000 | $-213,027,000 | $-155,063,000 | $-183,867,000 |
| Per Share | ||||
| Diluted EPS | $-3.05 | $-2.88 | $-2.65 | $-3.71 |
| Basic EPS | $-3.05 | $-2.88 | $-2.65 | $-3.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-266,810,000 | $-196,599,000 | $-141,409,000 | $-173,059,000 |
| Reconciled Depreciation | $18,856,000 | $16,428,000 | $13,654,000 | $10,808,000 |
| EBITDA (Bullshit earnings) | $-266,810,000 | $-196,599,000 | $-141,409,000 | $-173,059,000 |
| EBIT | $-285,666,000 | $-213,027,000 | $-155,063,000 | $-183,867,000 |
| Diluted Average Shares | $86,666,907 | $67,120,266 | $54,337,901 | $48,607,990 |
| Basic Average Shares | $86,666,907 | $67,120,266 | $54,337,901 | $48,607,990 |
| Diluted NI Availto Com Stockholders | $-264,457,000 | $-193,569,000 | $-143,948,000 | $-180,360,000 |
| Tax Provision | $760,000 | $270,000 | $0 | $0 |
| Research And Development | $316,903,000 | $221,632,000 | $189,148,000 | $184,497,000 |
| Selling General And Administration | $52,743,000 | $45,944,000 | $42,902,000 | $37,997,000 |
| Other Gand A | $52,743,000 | $45,944,000 | $42,902,000 | $37,997,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $538,747,000 | $526,993,000 | $200,493,000 | $303,696,000 |
| Total Assets | $688,135,000 | $669,343,000 | $355,598,000 | $416,759,000 |
| Total Non Current Assets | $81,316,000 | $49,956,000 | $60,095,000 | $98,310,000 |
| Other Non Current Assets | $8,309,000 | $4,060,000 | $4,724,000 | $4,923,000 |
| Current Assets | $606,819,000 | $619,387,000 | $295,503,000 | $318,449,000 |
| Other Current Assets | $13,878,000 | $9,804,000 | $7,595,000 | $9,308,000 |
| Cash Cash Equivalents And Short Term Investments | $592,941,000 | $609,583,000 | $287,908,000 | $309,141,000 |
| Cash And Cash Equivalents | $246,960,000 | $109,997,000 | $54,627,000 | $64,474,000 |
| Investmentin Financial Assets | - | $0 | $7,421,000 | $63,879,000 |
| Receivables | - | - | - | $0 |
| Taxes Receivable | - | - | - | $0 |
| Accounts Receivable | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $55,730,000 | $28,303,000 | $30,614,000 | $11,964,000 |
| Long Term Debt And Capital Lease Obligation | $52,906,000 | $20,289,000 | $23,125,000 | $6,434,000 |
| Current Debt And Capital Lease Obligation | $2,824,000 | $8,014,000 | $7,489,000 | $5,530,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $149,388,000 | $142,350,000 | $155,105,000 | $113,063,000 |
| Total Non Current Liabilities Net Minority Interest | $62,917,000 | $46,496,000 | $68,147,000 | $42,408,000 |
| Non Current Deferred Liabilities | $10,011,000 | $26,207,000 | $45,022,000 | $35,974,000 |
| Current Liabilities | $86,471,000 | $95,854,000 | $86,958,000 | $70,655,000 |
| Other Current Liabilities | $2,096,000 | $2,275,000 | $751,000 | $1,503,000 |
| Current Deferred Liabilities | $17,580,000 | $38,364,000 | $48,098,000 | $37,633,000 |
| Payables And Accrued Expenses | $42,430,000 | $30,570,000 | $15,317,000 | $12,825,000 |
| Payables | $12,274,000 | $12,719,000 | $6,431,000 | $5,149,000 |
| Total Tax Payable | $1,059,000 | $1,237,000 | $30,000 | $85,000 |
| Accounts Payable | $11,215,000 | $11,482,000 | $6,401,000 | $5,064,000 |
| Equity | ||||
| Common Stock Equity | $538,747,000 | $526,993,000 | $200,493,000 | $303,696,000 |
| Total Equity Gross Minority Interest | $538,747,000 | $526,993,000 | $200,493,000 | $303,696,000 |
| Stockholders Equity | $538,747,000 | $526,993,000 | $200,493,000 | $303,696,000 |
| Gains Losses Not Affecting Retained Earnings | $105,000 | $150,000 | $-655,000 | $-4,319,000 |
| Other Equity Adjustments | $105,000 | $150,000 | $-655,000 | $-4,319,000 |
| Retained Earnings | $-1,003,226,000 | $-738,769,000 | $-545,200,000 | $-401,252,000 |
| Other | ||||
| Ordinary Shares Number | $101,807,484 | $75,870,718 | $48,718,552 | $47,172,299 |
| Share Issued | $101,807,484 | $75,870,718 | $48,718,552 | $47,172,299 |
| Tangible Book Value | $538,747,000 | $526,993,000 | $200,493,000 | $303,696,000 |
| Invested Capital | $538,747,000 | $526,993,000 | $200,493,000 | $303,696,000 |
| Working Capital | $520,348,000 | $523,533,000 | $208,545,000 | $247,794,000 |
| Capital Lease Obligations | $55,730,000 | $28,303,000 | $30,614,000 | $11,964,000 |
| Total Capitalization | $538,747,000 | $526,993,000 | $200,493,000 | $303,696,000 |
| Additional Paid In Capital | $1,541,766,000 | $1,265,536,000 | $746,299,000 | $709,220,000 |
| Capital Stock | $102,000 | $76,000 | $49,000 | $47,000 |
| Common Stock | $102,000 | $76,000 | $49,000 | $47,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $10,011,000 | $26,207,000 | $45,022,000 | $35,974,000 |
| Long Term Capital Lease Obligation | $52,906,000 | $20,289,000 | $23,125,000 | $6,434,000 |
| Current Deferred Revenue | $17,580,000 | $38,364,000 | $48,098,000 | $37,633,000 |
| Current Capital Lease Obligation | $2,824,000 | $8,014,000 | $7,489,000 | $5,530,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $21,541,000 | $16,631,000 | $15,303,000 | $13,164,000 |
| Current Accrued Expenses | $30,156,000 | $17,851,000 | $8,886,000 | $7,676,000 |
| Net PPE | $73,007,000 | $45,896,000 | $47,950,000 | $29,508,000 |
| Accumulated Depreciation | $-37,782,000 | $-34,502,000 | $-26,249,000 | $-19,670,000 |
| Gross PPE | $110,789,000 | $80,398,000 | $74,199,000 | $49,178,000 |
| Leases | $9,369,000 | $5,140,000 | $3,238,000 | $3,825,000 |
| Construction In Progress | $141,000 | $497,000 | $587,000 | $697,000 |
| Other Properties | $94,090,000 | $67,170,000 | $63,381,000 | $38,730,000 |
| Machinery Furniture Equipment | $7,189,000 | $7,591,000 | $6,993,000 | $5,926,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $345,981,000 | $499,586,000 | $233,281,000 | $244,667,000 |
| Investments And Advances | - | $0 | $7,421,000 | $63,879,000 |
| Available For Sale Securities | - | - | $7,421,000 | $63,879,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-263,467,000 | $-181,857,000 | $-89,766,000 | $-172,051,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-249,465,000 | $-172,584,000 | $-81,365,000 | $-159,807,000 |
| Cash Flow From Continuing Operating Activities | $-249,465,000 | $-172,584,000 | $-81,365,000 | $-159,807,000 |
| Operating Gains Losses | $89,000 | $31,000 | $556,000 | $9,000 |
| Investing Activities | ||||
| Capital Expenditure | $-14,002,000 | $-9,273,000 | $-8,401,000 | $-12,244,000 |
| Investing Cash Flow | $147,853,000 | $-257,713,000 | $68,301,000 | $27,198,000 |
| Cash Flow From Continuing Investing Activities | $147,853,000 | $-257,713,000 | $68,301,000 | $27,198,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $234,762,000 | $478,495,000 | $0 | $114,159,000 |
| Financing Cash Flow | $238,642,000 | $485,667,000 | $3,217,000 | $117,192,000 |
| Cash Flow From Continuing Financing Activities | $238,642,000 | $485,667,000 | $3,217,000 | $117,192,000 |
| Net Common Stock Issuance | $234,762,000 | $478,495,000 | $0 | $114,159,000 |
| Common Stock Issuance | $234,762,000 | $478,495,000 | $0 | $114,159,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $247,928,000 | $110,898,000 | $55,528,000 | $65,375,000 |
| Beginning Cash Position | $110,898,000 | $55,528,000 | $65,375,000 | $80,792,000 |
| Changes In Cash | $137,030,000 | $55,370,000 | $-9,847,000 | $-15,417,000 |
| Proceeds From Stock Option Exercised | $3,880,000 | $7,172,000 | $3,217,000 | $3,033,000 |
| Net Investment Purchase And Sale | $161,855,000 | $-248,440,000 | $76,702,000 | $39,442,000 |
| Sale Of Investment | $617,543,000 | $459,513,000 | $323,036,000 | $278,808,000 |
| Purchase Of Investment | $-455,688,000 | $-707,953,000 | $-246,334,000 | $-239,366,000 |
| Net PPE Purchase And Sale | $-14,002,000 | $-9,273,000 | $-8,401,000 | $-12,244,000 |
| Purchase Of PPE | $-14,002,000 | $-9,273,000 | $-8,401,000 | $-12,244,000 |
| Change In Working Capital | $-31,596,000 | $-18,401,000 | $20,121,000 | $-19,022,000 |
| Change In Other Working Capital | $-36,980,000 | $-28,549,000 | $19,513,000 | $-26,627,000 |
| Change In Other Current Liabilities | $-5,067,000 | $-6,418,000 | $-6,268,000 | $-4,871,000 |
| Change In Payables And Accrued Expense | $16,680,000 | $17,025,000 | $4,737,000 | $7,570,000 |
| Change In Accrued Expense | $17,310,000 | $11,816,000 | $3,123,000 | $7,485,000 |
| Change In Payable | $-630,000 | $5,209,000 | $1,614,000 | $85,000 |
| Change In Account Payable | $-630,000 | $5,209,000 | $1,614,000 | $85,000 |
| Change In Prepaid Assets | $-6,229,000 | $-459,000 | $2,139,000 | $-1,094,000 |
| Stock Based Compensation | $37,965,000 | $33,929,000 | $33,673,000 | $28,131,000 |
| Amortization Of Securities | $-10,322,000 | $-11,288,000 | $-5,421,000 | $426,000 |
| Depreciation Amortization Depletion | $18,856,000 | $16,428,000 | $13,654,000 | $10,808,000 |
| Depreciation And Amortization | $18,856,000 | $16,428,000 | $13,654,000 | $10,808,000 |
| Depreciation | $18,856,000 | $16,428,000 | $13,654,000 | $10,808,000 |
| Gain Loss On Sale Of PPE | $89,000 | $31,000 | $556,000 | $9,000 |
| Net Income From Continuing Operations | $-264,457,000 | $-193,569,000 | $-143,948,000 | $-180,360,000 |
| Change In Receivables | - | $0 | $0 | $6,000,000 |
| Changes In Account Receivables | - | $0 | $0 | $6,000,000 |
| Other Non Cash Items | - | $286,000 | - | $201,000 |
| Income Tax Paid Supplemental Data | - | - | - | $0 |
Fetched: 2026-06-23